Device Consortium Addresses Barriers To Early U.S. Feasibility Studies, MDIC’s Murray Tells Congress
This article was originally published in The Gray Sheet
Executive Summary
Medical Device Innovation Consortium President and CEO Bill Murray testified about MDIC and FDA’s plans to promote early feasibility studies of products in the U.S., rather than abroad, at a recent House Energy and Commerce panel hearing.
You may also be interested in...
AIM Act Touted As One Solution To Device Reimbursement Woes
The Accelerating Innovation in Medicine Act, introduced last year with some bipartisan support, was touted at the latest House 21st Century Cures hearing as a self-pay path for seniors to get access to newly-approved devices not yet covered under Medicare, and to give manufacturers time to collect needed data to support reimbursement.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.